Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 and CD22 Targeted CAR-T for R/R B-Cell Malignancies
NCT04648475Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Aug 2020
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 and CD22 targeted CAR-T cells in B-cell leukemia (BCL), B cell lymphoma, sponsored by Chongqing Precision Biotech. Status: unknown.
02
Drugs
CD19 and CD22 targeted CAR-T cells
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT04648475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648475.